Dendreon Pharmaceuticals LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$16.3M
Doctors Paid
9,514
Transactions
61,024
2024 Total
$1.8M
Payment Breakdown by Category
Research$11.5M (70.7%)
Food & Beverage$1.6M (10.1%)
Consulting$959,142 (5.9%)
Travel$239,345 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.5M | 1,762 | 70.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 896 | 11.8% |
| Food and Beverage | $1.6M | 57,082 | 10.1% |
| Consulting Fee | $959,142 | 406 | 5.9% |
| Travel and Lodging | $239,345 | 742 | 1.5% |
| Education | $2,108 | 136 | 0.0% |
Payments by Type
Research
$11.5M
1,762 transactions
General
$4.8M
59,262 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT | $3.2M | 0 | 295 |
| A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER | $2.9M | 0 | 751 |
| OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER (PROVENT) | $2.4M | 0 | 392 |
| A RANDOMIZED PHASE 2 STUDY OF SIPULEUCEL-T WITH OR WITHOUT RADIUM-223 IN MEN WITH ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC BONE-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $695,523 | 0 | 14 |
| ProvONE Study | $684,938 | 0 | 88 |
| A RANDOMIZED PHASE 2 TRIAL OF IMMEDIATE VS. DELAYED ANTI-CTLA4 BLOCKADE FOLLOWING SIPULEUCEL-T TREATMENT FOR PROSTATE CANCER IMMUNOTHERAPY | $213,299 | 0 | 5 |
| A STUDY TO EVALUATE CHARACTERISTICS PREDICTIVE OF A POSITIVE IMAGING STUDY FOR DISTANT METASTASES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREDICT | $177,661 | 1 | 72 |
| BIOLOGIC TISSUE EFFECT OF SIPULEUCEL-T ON METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $147,752 | 0 | 9 |
| Biologic Tissue Effect OF Sipuleucel-T on Metastatic Castration-resistant Prostate Cancer | $147,686 | 0 | 2 |
| EVALUATION OF LYMPH NODE METASTAASES IN MEN UNDERGOING TREATMENT WITH SIPULEUCEL-T FOR METASTATIC CASTRATED-RESISTANT PROSTATE CANCER | $138,222 | 0 | 1 |
| IMMUNE EVALUATION STUDY OF SIPULEUCEL-T IN AFRICAN AMERICAN MEN WITH CASTRATE RESISTANT PROSTATE CANCER | $127,500 | 0 | 1 |
| CLINICAL STUDY OF ATEZOLIZUMAB ANTI-PD-L1 AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $120,135 | 0 | 9 |
| A Phase II CTLA4 Blockade Combined with Sipuleucel-T (Provenge) for Prostate Cancer Immunotherapy | $91,720 | 0 | 2 |
| RETROSPECTIVE REVIEW EVALUATING THE PSA CHANGES IN PATIENT WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER AFTER SIPULEUCEL-T TREATMENT | $79,514 | 0 | 1 |
| CYT107 AFTER VACCINE TREATMENT PROVENGE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $66,796 | 0 | 1 |
| ROSSER-2015-4CLINICAL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1) AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $58,159 | 0 | 2 |
| IMPACT OF HIGH-DOSE, SINGLE FRACTION RADIATION ON IMMUNOGENICITY OF SIPULEUCEL-T IN METASTATIC CASTRATION RECURRENT PROSTATE CANCER PATIENTS | $42,609 | 0 | 1 |
| A PHASE II CTLA4 BLOCKADE COMBINED WITH SIPULEUCEL-T PROVENGE FOR PROSTATE CANCER IMMUNOTHERAPY | $41,477 | 0 | 1 |
| A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ABIRATERONE ACETATE PLUS PREDNISONE IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $31,613 | 0 | 49 |
| A PHASE II RANDOMIZED STUDY OF SIPULEUCEL-T WITH OR WITHOUT CONTINUING NEW HORMONAL AGENTS (NHA) IN METASTATIC PROSTATE CANCER WITH PSA PROGRESSION WHILE ON NHA AND LHRH ANALOG | $31,245 | 0 | 1 |
| A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER | $28,120 | 0 | 21 |
| PILOT TRIAL OF SIPULEUCEL-T, WITH OR WITHOUT PTVG-HP DNA BOOSTER VACCINE, IN PATIENTS WITH CASTRATE-RESISTANT, METASTATIC PROSTATE CANCER | $26,266 | 0 | 1 |
| CLINICAL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1) AND SIPULEUCEL-T IN PATIENTS WHO HAVE ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER | $19,645 | 0 | 4 |
| A STUDY OF SIPULEUCEL-T WITH ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $14,454 | 0 | 4 |
| A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF SIPULEUCEL-T WITH CONCURRENT VERSUS SEQUENTIAL ADMINISTRATION OF ENZALUTAMIDE IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $11,680 | 0 | 25 |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2 Urothelial Carcinoma | $6,845 | 0 | 1 |
| IMMUNE MONITORING PROTOCOL IN MEN WITH PROSTATE CANCER ENROLLED IN A CLINICAL TRIAL OF SIPULEUCEL-T | $1,539 | 0 | 8 |
| A SYSTEMS BIOLOGY APPROACH TO IMMUNE MONITORING IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER RECEIVING SIPULEUCEL-T | $1,200 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Judd Moul, M.d, M.D | Urology | Durham, NC | $252,626 | $0 |
| Dr. Jonathan Hamilton, M.d, M.D | Urology | Greenville, NC | $174,016 | $0 |
| Vahan Kassabian, M.d, M.D | Urology | Roswell, GA | $169,682 | $0 |
| William Berry, M.d, M.D | Medical Oncology | Raleigh, NC | $127,121 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $123,655 | $0 |
| Jason Hafron, Md, MD | Urology | West Bloomfield, MI | $122,764 | $0 |
| Bryan Mehlhaff, Md, MD | Urology | Springfield, OR | $119,217 | $0 |
| Paul Eber, M.d, M.D | Urology | Germantown, TN | $110,184 | $0 |
| Mr. Jim Hsiang, Md, MD | Specialist | Corpus Christi, TX | $98,918 | $0 |
| Richard Harris, M.d, M.D | Urology | Melrose Park, IL | $79,955 | $0 |
| Paul Dato, M.d, M.D | Urology | La Mesa, CA | $75,867 | $0 |
| Michael Fabrizio, M.d, M.D | Urology | Washington, DC | $68,309 | $0 |
| Dr. Russell Pachynski, Md, MD | Medical Oncology | Saint Louis, MO | $67,294 | $0 |
| Christopher Pieczonka, M.d, M.D | Urology | Syracuse, NY | $55,941 | $0 |
| Kenneth Kernen, Md, MD | Urology | Troy, MI | $55,823 | $0 |
| Benjamin Lowentritt, M.d, M.D | Urology | Baltimore, MD | $54,758 | $0 |
| Paul Sieber, M.d, M.D | Urology | Lancaster, PA | $54,137 | $0 |
| Raoul Concepcion, Md, MD | Urology | Nashville, TN | $49,419 | $0 |
| Elward Crawford, Md, MD | Urology | San Diego, CA | $49,325 | $0 |
| Dr. Roman Nation, Md, MD | Family Medicine | Panama City, FL | $48,000 | $0 |
| Dr. Benjamin Martin, Md, MD | Urology | Gahanna, OH | $45,045 | $0 |
| Lawrence Gervasi, Md, MD | Urology | Middleburg Heights, OH | $44,305 | $0 |
| Dr. Vincent Bivins, Md, MD | Urology | Homewood, AL | $44,303 | $0 |
| Dr. David Morris, Md, MD | Student in an Organized Health Care Education/Training Program | Hendersonville, TN | $43,859 | $0 |
| Dr. Richard Harris, M.d, M.D | Internal Medicine | Chicago, IL | $42,560 | $0 |
About Dendreon Pharmaceuticals LLC
Dendreon Pharmaceuticals LLC has made $16.3M in payments to 9,514 healthcare providers, recorded across 61,024 transactions in the CMS Open Payments database. In 2024, the company paid $1.8M. The top product by payment volume is PROVENGE ($16.1M).
Payments were distributed across 144 medical specialties. The top specialty by payment amount is Urology ($3.3M to 3,858 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($959,142), Research ($11.5M), Travel & Lodging ($239,345).
Dendreon Pharmaceuticals LLC is associated with 1 products in the CMS Open Payments database.